Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

被引：2

作者：

Mansilla-Polo, Miguel ^{[1
,2
]}

Pons-Benavent, Marti ^{[3
]}

Fernandez-Crehuet, Pablo ^{[4
]}

Vilarrasa, Eva ^{[5
]}

Albanell-Fernandez, Cristina ^{[6
]}

Morales-Tedone, Enrico ^{[6
]}

Rausell-Felix, Francisca ^{[6
]}

Alcala-Garcia, Rebeca ^{[7
]}

Matellanes-Palacios, Maria ^{[7
]}

Martin-Ezquerra, Gemma ^{[8
]}

Alfageme, Fernando ^{[9
]}

Ciudad-Blanco, Cristina ^{[10
]}

Lopez-Villaescusa, Maria Teresa ^{[11
]}

Garbayo-Salmons, Patricia ^{[12
]}

Martorell, Antonio ^{[13
]}

Escutia-Munoz, Begona ^{[1
,2
]}

Navarro-Blanco, Fernando ^{[1
,2
]}

Martin-Torregrosa, Daniel ^{[1
,2
]}

Cuenca-Barrales, Carlos ^{[14
]}

Molina-Leyva, Alejandro ^{[14
]}

Botella-Estrada, Rafael ^{[1
,2
,15
]}

机构：

[1] Hosp Univ & Politecn La Fe, Dept Dermatol, 106 Ave Fernando Abril Martorell, Valencia 46026, Spain

[2] Inst Invest Sanitaria IIS La Fe, Valencia, Spain

[3] Hosp Virgen Lirios, Dept Dermatol, Alicante, Spain

[4] Hosp Reina Sofia, Dept Dermatol, Cordoba, Spain

[5] Hosp Santa Creu St Pau, Dept Dermatol, Barcelona, Spain

[6] Hosp Clin Univ, Dept Dermatol, Valencia, Spain

[7] Hosp Sagunto, Dept Dermatol, Valencia, Spain

[8] Hosp Mar, Dept Dermatol, Barcelona, Spain

[9] Hosp Univ Puerta Hierro, Dept Dermatol, Madrid, Spain

[10] Hosp Univ Gregorio Maranon, Dept Dermatol, Madrid, Spain

[11] Complejo Hosp Univ Albacete, Dept Dermatol, Albacete, Spain

[12] Hosp Parc Tauli Sabadell, Dept Dermatol, Barcelona, Spain

[13] Hosp Manises, Dept Dermatol, Valencia, Spain

[14] Hosp Univ Virgen Nieves, Dept Dermatol, Granada, Spain

[15] Univ Valencia, Fac Med, Valencia, Spain

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2024年 / 65卷 / 07期

关键词：

bimekizumab; biologic therapy; effectiveness; hidradenitis suppurativa; safety;

D O I：

10.1111/ajd.14339

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.

引用

页码：e198 / e202

页数：5

共 50 条

[31] Metabolic Disorders/Obesity Is a Primary Risk Factor in Hidradenitis Suppurativa: An Immunohistochemical Real-World Approach [J].

Kaleta, Katarzyna P. ;

Nikolakis, Georgios ;

Hossini, Amir M. ;

Balthasar, Ottfried ;

Almansouri, Daifallah ;

Vaiopoulos, Aristeidis ;

Knolle, Jurgen ;

Boguslawska, Anna ;

Wojas-Pelc, Anna ;

Zouboulis, Christos C. .

DERMATOLOGY, 2022, 238 (02) :251-259

[32] Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study [J].

Haselgruber, Sofia ;

Fernandez-Crehuet-Serrano, Pablo ;

Fernandez-Ballesteros, Maria Dolores ;

Padial-Gomez, Alicia ;

Hernandez-Rodriguez, Juan Carlos ;

Ortiz-alvarez, Juan ;

Navarro-Guillamon, Pedro ;

Membrive-Jimenez, Cristina ;

Cuenca-Barrales, Carlos ;

Molina-Leyva, Alejandro .

DERMATOLOGY AND THERAPY, 2024, 14 (07) :1875-1890

[33] Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study [J].

Potestio, Luca ;

Ruggiero, Angelo ;

Martora, Fabrizio ;

Megna, Matteo .

ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 317 (01)

[34] Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence [J].

Parikh, Raunak ;

Singer, David ;

Chmielewski-Yee, Elizabeth ;

Dessart, Christophe .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)

[35] Long-Term Safety and Effectiveness of Diquafosol for the Treatment of Dry Eye in a Real-World Setting: A Prospective Observational Study [J].

Yuichi Ohashi ;

Masahiro Munesue ;

Jun Shimazaki ;

Etsuko Takamura ;

Norihiko Yokoi ;

Hitoshi Watanabe ;

Akio Nomura ;

Fumiki Shimada .

Advances in Therapy, 2020, 37 :707-717

[36] Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan [J].

Kobayashi, Shigeto ;

Kashiwagi, Tomoko ;

Kimura, Junko .

MODERN RHEUMATOLOGY, 2019, 29 (06) :1007-1012

[37] Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study [J].

Bedke, Jens ;

Grimm, Marc-Oliver ;

Gruenwald, Viktor .

FUTURE ONCOLOGY, 2018, 14 (11) :1023-1034

[38] Long-Term Safety and Effectiveness of Diquafosol for the Treatment of Dry Eye in a Real-World Setting: A Prospective Observational Study [J].

Ohashi, Yuichi ;

Munesue, Masahiro ;

Shimazaki, Jun ;

Takamura, Etsuko ;

Yokoi, Norihiko ;

Watanabe, Hitoshi ;

Nomura, Akio ;

Shimada, Fumiki .

ADVANCES IN THERAPY, 2020, 37 (02) :707-717

[39] A real-world analysis of roxadustat effectiveness and safety in managing renal anemia among patients on maintenance hemodialysis: An observational study [J].

Zhang, Yuan ;

Chen, Minyue ;

Tang, Lian ;

Chen, Xiangfan ;

Meng, Yajing ;

Feng, Sujuan .

MEDICINE, 2024, 103 (31) :e39203

[40] Effectiveness and Safety of a Clonidine Adhesive Patch for Children With Tic Disorders: Study in a Real-World Practice [J].

Yang, Chunsong ;

Kang, BingYao ;

Yu, Dan ;

Zhao, Li ;

Zhang, Lingli .

FRONTIERS IN NEUROLOGY, 2020, 11

← 1 2 3 4 5 →